On the stock market since 2021, it operates in the world of health and science. It has 56 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
The stock has been running stronger than the market lately.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Business Quality: Profit power and business quality trail similar companies in the sector.
An investor who bought at the very peak is down 77% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $13.9M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 13 buys and 5 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $6.50 — 108% above today’s price.
A loss of $79.6M against $13.9M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, PYXS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PYXS is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (15/100) says the stock isn’t cheap.